Please use this identifier to cite or link to this item: http://arl.liuc.it/dspace/handle/2468/6904
Title: Cost of relapse management in patients with schizophrenia in Italy and Spain: comparison between lurasidone and quetiapine XR
Authors: Restelli, Umberto
García-Goñi, Manuel
Lew-Starowicz, Michal
Mierzejewski, Pawel
Silvola, Sofia
Mayoral-van Son, Jacqueline
Croce, Davide
Rocca, Paola
Crespo-Facorro, Benedicto
Issue Date: 2020
Publisher: Springer
Bibliographic citation: Restelli Umberto, et al. (2020), Cost of relapse management in patients with schizophrenia in Italy and Spain: comparison between lurasidone and quetiapine XR. In: Clinical drug investigation. Published electronically 9 July 2020, p. 1-11. ISSN 1173-2563. E-ISSN 1179-1918. DOI 10.1007/s40261-020-00944-0.
Abstract: Background and Objective: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to investigate how the results of clinical studies translate into direct medi-cal costs. The objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine XR (300 mg) assuming the Italian and Spanish National Health Service perspective. Methods: A health economic model was developed based on a previously published model. The analysis considered direct medical costs related to the pharmacological therapies and inpatient or outpatient management of relapses (direct medical costs referred to 2019). The probability of relapses and related costs were derived from two systematic reviews. A determin-istic sensitivity analysis was implemented to test the robustness of the results. Results: The use of lurasidone (74 mg) compared with quetiapine XR (300 mg) would lead to a reduction in direct medical costs in Italy and Spain, with a lower cost per patient of − 163.7 € (− 9.0%) and − 327.2 € (− 22.7%), respectively. In detail, it would lead to an increase in the cost of therapy of + 53.8% and of + 30.5% in Italy and Spain, respectively, to a decrease in the cost of relapses with hospitalization of − 135.7%, and to an increase in the cost of relapses without hospitalization of + 24.5%. Conclusions: The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetia-pine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view.
URI: http://arl.liuc.it/dspace/handle/2468/6904
Journal/Book: Clinical drug investigation
Appears in Collections:Contributo in rivista

Files in This Item:
File Description SizeFormat 
6904.pdf
  Restricted Access
938,74 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.